Mystrelle (Ethinylestradiol, Etonogestrel)

Ethinylestradiol and etonogestrel, the active ingredients in Mystrelle, are a combined estrogen‑progestogen contraceptive presented as a vaginal ring for intravaginal use. Approved in the European Union, the device delivers a steady hormone dose to prevent pregnancy in women of reproductive age by suppressing ovulation and altering cervical mucus.

GNH USA supplies Mystrelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality‑assurance protocols and providing regulatory documentation for cross‑border distribution and reliable logistics support.

Mystrelle, a combined estrogen‑progestogen contraceptive, is used to prevent pregnancy and manage hormone‑related menstrual conditions.

- Contraception: prevents pregnancy by inhibiting ovulation and thickening cervical mucus. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces cycle‑related pain. - Acne management: reduces androgen‑driven acne lesions in women using hormonal contraception.

Like all hormonal contraceptives, Mystrelle may be associated with a range of adverse reactions.

Common Side Effects: - Vaginal discharge or irritation: mild irritation or increased discharge at the insertion site. - Headache: transient tension‑type or migraine‑like headaches. - Nausea: occasional mild nausea, especially during initial cycles. - Breast tenderness: temporary swelling or tenderness of the breasts. - Mood changes: mild mood swings or irritability.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack: cerebrovascular events. - Hepatic adenoma: benign liver tumor development. - Severe allergic reaction: anaphylaxis or angioedema. - Hyperglycemia: significant rise in blood glucose in diabetic patients.

Before prescribing Mystrelle, clinicians should evaluate patient history and follow specific safety guidelines. - Smoking status: avoid use in women over 35 who smoke due to increased thrombotic risk. - Cardiovascular disease: contraindicated in patients with history of myocardial infarction or stroke. - Liver function: assess hepatic impairment as metabolism occurs in the liver. - Migraine with aura: contraindicated because of elevated stroke risk. - Breast cancer history: avoid in current or past estrogen‑dependent breast cancer. - Store at below 25°C: keep the vaginal ring in its original packaging, protect from moisture and direct sunlight.

Mystrelle can interact with other medicines that affect hormone metabolism or increase clotting risk.

Major Interactions (Avoid): - Anticoagulants: may reduce effectiveness of warfarin, requiring close INR monitoring. - Enzyme inducers: rifampicin, carbamazepine, phenytoin can lower hormone levels, decreasing contraceptive efficacy. - High‑dose SSRIs: may increase risk of serotonin syndrome when combined with hormonal agents.

Moderate Interactions (Monitor Closely): - Antifungals (ketoconazole, itraconazole): can increase hormone concentrations, potentially heightening side‑effect risk. - Antiretrovirals (efavirenz): may reduce contraceptive effectiveness. - Herbal supplements (St. John’s wort): may diminish hormone levels, requiring alternative contraception.